Bio-Techne Corporation (TECH)
$
58.63
-0.10 (-0.17%)
Key metrics
Financial statements
Free cash flow per share
1.6051
Market cap
9.3 Billion
Price to sales ratio
7.7497
Debt to equity
0.1891
Current ratio
3.9356
Income quality
1.9271
Average inventory
186.7 Million
ROE
0.0761
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Bio-Techne Corporation, along with its subsidiaries, specializes in the development, manufacture, and sale of life science reagents, instruments, and services targeting the research and clinical diagnostics sectors globally. The company operates through two primary segments: Protein Sciences and Diagnostics and Genomics. In the Protein Sciences segment, Bio-Techne develops and manufactures biological reagents utilized in various facets of life science research, diagnostics, and cell and gene therapies. This includes cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. Additionally, this segment provides proteomic analytical tools that facilitate automated western blotting and multiplexed ELISA workflows, comprising both manual and automated protein analysis instruments as well as immunoassays designed to quantify proteins across multiple biological fluids. In its Diagnostics and Genomics segment, Bio-Techne is engaged in the development and manufacture of diagnostic products including controls, calibrators, and diagnostic assays tailored for the regulated diagnostics market. This segment also focuses on exosome-based molecular diagnostics, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, along with genetic and oncology kits suitable for research and clinical applications. The company reported a net income of $168,105,000.00 reflecting its profitability, while also earning an interest income of $3,323,000.00 showcasing its financial investments. The earnings per share (EPS) is reported at $1.07 indicating the company's profitability on a per-share basis. However, it incurred an interest expense of $15,736,000.00 reflecting its debt servicing obligations. The total operating expenses amount to $563,039,000.00 encompassing various operational costs incurred throughout its business operations. Bio-Techne is characterized by a stock deemed reasonably priced at $58.06 which is appealing to a broad range of investors. The stock also enjoys an average trading volume of 1,583,728.00 indicating moderate liquidity in the market. With a mid-range market capitalization of $9,268,699,440.00 the company stands out as a steady performer in the life sciences field. It plays a pivotal role in the Biotechnology industry, contributing significantly to the overall market landscape. Furthermore, it belongs to the Healthcare sector, driving innovation and growth within the life sciences arena.
What is Bio-Techne Corporation (TECH)'s stock forecast?
Analysts predict Bio-Techne Corporation stock to fluctuate between $56.60 (low) and $85.57 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Bio-Techne Corporation's market capitalization?
As of 2025-04-01, Bio-Techne Corporation's market cap is $9,268,699,440, based on 158,088,000 outstanding shares.
How does Bio-Techne Corporation compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Bio-Techne Corporation has a Lower Market-Cap, indicating a difference in performance.
How can I buy Bio-Techne Corporation (TECH) stock?
To buy Bio-Techne Corporation (TECH) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for TECH. Place an order (Market, Limit, etc.).
What is the best time to invest in Bio-Techne Corporation?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did Bio-Techne Corporation perform in the last earnings report?
Revenue: $1,159,060,000 | EPS: $1.07 | Growth: -40.88%.
Where can I find Bio-Techne Corporation's investor relations reports?
Visit https://www.bio-techne.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Bio-Techne Corporation?
You can explore historical data from here
What is the all-time high and low for Bio-Techne Corporation stock?
All-time high: $362.53 (2022-11-11) | All-time low: $51.79 (2023-11-01).
What are the key trends affecting Bio-Techne Corporation stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
zacks.com
TECH announces the opening of a new Customer Experience Centre to support long-term growth in the EMEA region. The new facility is located in Dusseldorf, Germany.
globenewswire.com
CMB.TECH ANNOUNCES FINAL YEAR RESULTS TRANSFORMATIONAL YEAR AND STRONG EARNINGS ANTWERP, Belgium, 27 March 2025 – CMB.TECH NV (“CMBT”, “CMB.TECH” or “the Company”) (NYSE: CMBT & Euronext: CMBT) reported its final financial results today for the full year ended 31 December 2024. HIGHLIGHTS 2024 Profit of USD 93.1 million in Q4 2024 bringing full year profit to USD 870.8 million Total contract backlog increased to USD 2.94 billion Name change from Euronav to CMB.TECH (ticker symbol CMBT) CMB.TECH focused on its fleet rejuvenation with 21 newbuild deliveries Further fleet expansion with 1 container vessel, 2 dry bulk carriers, 2 product tankers, 6 chemical tankers and 2 CTVs contracted in 2024 & Q1 2025 Sale of 6 older Suezmaxes, 4 older VLCCs and 1 container vessel New hydrogen engine R&D Center in Japan Sale of Euronav Ship Management Hellas (ESMH) to Anglo- Eastern Univan Group HIGHLIGHTS Q1 2025 CMB.TECH joins forces with MOL to jointly own and charter a total of 9 ammonia-fuelled vessels Share purchase agreement with Hemen Holding Limited for the acquisition of 81,363,730 shares in Golden Ocean Group Limited For the fourth quarter of 2024, the company realised a net gain of USD 93.1 million or USD 0.48 per share (fourth quarter 2023: a net gain of USD 406.6 million or USD 2.01 per share).
globenewswire.com
Antwerp, March 24, 2025 (GLOBE NEWSWIRE) -- CMB.TECH NV (“CMBT”, “CMB.TECH” or “the Company”) (NYSE: CMBT & Euronext: CMBT) is pleased to announce that it has signed an agreement with Mitsui O.S.K. Lines, Ltd. (“MOL”) and MOL CHEMICAL TANKERS PTE. LTD. (“MOLCT”) for nine ammonia-powered vessels. These vessels will be among the world's first ammonia-powered Newcastlemax bulk carriers and chemical tankers. The delivery of these ships is expected between 2026 and 2029.
globenewswire.com
Belgium, March 04, 2025 (GLOBE NEWSWIRE) -- CMB.TECH NV (NYSE: CMBT & Euronext: CMBT) (“CMB.TECH” or the “Company”) is pleased to announce that it has entered into a share purchase agreement with Hemen Holding Limited (“Hemen”), for the acquisition of 81,363,730 shares in Golden Ocean Group Limited (“Golden Ocean”) (NASDAQ: GOGL & Euronext: GOGL) (representing ca. 40.8%[1] of Golden Ocean's outstanding shares and votes which includes all Golden Ocean shares controlled by Hemen), at a price of 14.49 USD per share (the “Transaction”).
prnewswire.com
SCOTTSDALE, Ariz. , Feb. 27, 2025 /PRNewswire/ -- Cyber Enviro-Tech Inc. (CETI) (OTCQB: CETI) is pleased to announce the formation of a Turkish subsidiary, Cyber International Ltd (C-INT), with an office in Istanbul, Turkey.
globenewswire.com
CMB.TECH ANNOUNCES Q4 2024 RESULTS STRONG RESULTS DESPITE SLOW MARKETS ANTWERP, Belgium, 27 February 2025 – CMB.TECH NV (“CMBT”, “CMB.TECH” or “the Company”) (NYSE: CMBT & Euronext: CMBT) reported its non-audited financial results today for the fourth quarter ended 31 December 2024. HIGHLIGHTS Profit of USD 93.1 million in Q4 2024 bringing YTD profit to USD 870.8 million Delivery of 7 newbuilding vessels Sale of 4 Suezmaxes Selena (2007, 150,205 dwt), Cap Victor (2007, 158,853 dwt), Cap Felix (2008, 158,765 dwt) & Cap Lara (2007, 158,826 dwt) Sale of Windcat 6 For the fourth quarter of 2024, the company realised a net gain of USD 93.1 million or USD 0.48 per share (fourth quarter 2023: a net gain of 406.6 USD million or USD 2.01 per share).
zacks.com
TECH unveils the RNAscope Probes menu for human and mouse transcriptome to advance spatial biology.
globenewswire.com
GUANGZHOU, China, Feb. 24, 2025 (GLOBE NEWSWIRE) -- YSX TECH. CO., LTD (the “Company” or “YSXT”), a Cayman Islands exempted company that, through its variable interest entities in China, provides comprehensive business solutions mainly for insurance companies and brokerages in China, today announced its unaudited financial results for the six months ended September 30, 2024.
globenewswire.com
Antwerp, Feb. 13, 2025 (GLOBE NEWSWIRE) -- CMB.TECH NV (NYSE: CMBT & Euronext: CMBT) (“CMBT”, “CMB.TECH” or “the Company”) will release its fourth quarter 2024 earnings prior to market opening on Thursday 27 February 2025 and will host a conference call at 8 a.m. EST / 2 p.m. CET to discuss the results for the quarter.
See all news
